Account
Inquiry
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for metabolic research applications. This white powder formulation demonstrates superior efficacy in glucose control and weight management studies compared to selective GLP-1 receptor agonists.
The molecular structure features PEG modification on the lys side chain, enhancing water solubility while maintaining biological activity. As a research compound, tirzepatide has shown promising results in clinical studies, with weight reduction percentages ranging from 15-20.9% depending on dosage in controlled trials.
Our pharmaceutical grade tirzepatide is supplied in convenient 10mg vials (10 vials per box) with strict quality control measures. The compound exhibits greater affinity for GIP receptors compared to GLP-1 receptors, making it particularly interesting for metabolic research applications.
For laboratory use only. Not for human consumption. Researchers should follow proper peptide storage protocols including protection from light, moisture, and temperature extremes to maintain compound stability.
